XL
Live price temporarily unavailable.
Price history
Xilio Therapeutics (XLO) is a Health Care company. Latest news and coverage below.
IPO: October 22, 2021 · $16.00 offering · NASDAQ · View IPO details →
Xilio Therapeutics revenue & net income history (FY2020–FY2025)
RevenueNet income
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | $6.34M | $43.8M |
| Growth (year over year) | — | — | — | — | — | +589.9% |
| Operating income | −$54.6M | −$75.0M | −$89.1M | −$79.1M | −$60.6M | −$42.0M |
| Operating margin | — | — | — | — | −954.9% | −95.9% |
| Net income | −$55.2M | −$75.8M | −$88.2M | −$76.4M | −$58.2M | −$35.0M |
| Net margin | — | — | — | — | −918.0% | −80.1% |
| EPS (diluted) | −$105.42 | −$13.52 | −$3.22 | −$2.78 | −$15.24 | −$4.19 |
| Balance sheet | ||||||
| Cash and equivalents | $19.2M | $198.1M | $120.4M | $44.7M | $55.3M | $137.5M |
| Total assets | $36.3M | $218.1M | $139.2M | $60.9M | $71.1M | $154.7M |
| Total liabilities | $41.6M | $32.6M | $33.5M | $24.1M | $53.5M | $119.4M |
| Shareholders' equity | −$83.3M | $185.4M | $105.6M | $36.8M | $17.6M | $35.3M |
| Cash flow | ||||||
| Operating cash flow | −$36.1M | −$80.8M | −$75.7M | −$68.6M | −$18.4M | −$4.99M |
| Capital expenditure | $2.19M | $1.10M | $1.87M | $486.0K | $36.0K | $518.0K |
| Free cash flow | −$38.3M | −$81.9M | −$77.6M | −$69.1M | −$18.4M | −$5.51M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.26M | $1.72M | $2.93M | $8.08M | $19.1M | $13.7M | $12.6M | $18.7M |
| Growth (year over year) | — | — | — | +243.0% | +742.5% | +693.9% | +331.7% | +131.2% |
| Operating income | −$14.8M | −$13.6M | −$13.9M | −$14.4M | −$1.93M | −$11.8M | −$14.1M | −$3.49M |
| Operating margin | −652.3% | −790.5% | −472.7% | −177.7% | −10.1% | −86.5% | −111.6% | −18.7% |
| Net income | −$14.0M | −$13.1M | −$13.3M | −$15.8M | −$16.3M | $10.4M | −$9.53M | −$6.37M |
| Net margin | −619.5% | −759.5% | −452.7% | −196.0% | −85.4% | 75.7% | −75.3% | −34.1% |
| EPS (diluted) | −$0.22 | −$14.16 | −$2.49 | −$2.30 | −$0.11 | $0.71 | −$0.58 | −$0.33 |
| Balance sheet | ||||||||
| Cash and equivalents | $61.3M | $55.3M | $89.1M | $121.6M | $103.8M | $137.5M | $150.3M | $136.0M |
| Total assets | $74.7M | $71.1M | $103.7M | $133.8M | $133.7M | $154.7M | $163.5M | $154.3M |
| Total liabilities | $53.7M | $53.5M | $93.0M | $126.7M | $141.8M | $119.4M | $90.9M | $82.0M |
| Shareholders' equity | $21.0M | $17.6M | $10.7M | $7.07M | −$8.10M | $35.3M | $72.5M | $72.3M |
| Cash flow | ||||||||
| Operating cash flow | −$13.7M | −$14.2M | $29.0M | −$14.5M | −$17.5M | −$2.00M | −$22.3M | −$18.8M |
| Capital expenditure | $9.00K | $6.00K | $22.0K | $401.0K | $0 | $95.0K | $556.0K | $19.0K |
| Free cash flow | −$13.7M | −$14.2M | $29.0M | −$14.9M | −$17.5M | −$2.09M | −$22.9M | −$18.8M |
From Xilio Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Xilio Therapeutics
- Headquarters
- Waltham, Massachusetts From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International